Författare: Smith J Gustav, Koul Sasha, Kornhall Björn, Ekmehag Björn

Titel: ABC om kronisk hjärtsvikt, del 2: behandling (serie: Medicinens ABC) 2012 nr 41 sid 1829-34

Läs/ladda hem artikeln:
Översikt
Fullständig referenslista
Artikeln i pdf-format
Artikeln i webbversion
Sid 1829
Sid 1830
Sid 1831
Sid 1832
Sid 1833
Sid 1834
Om Läkartidningens fulltext på Internet
Ämnesord:
Hjärtsvikt
Vänsterkammardysfunktion
Hjärtstimulering, artificiell
Adrenerga betablockerare
Aldosteronblockerare
ACE-hämmare
Kronisk sjukdom
Kliniska vårdvägar
Defibrillatorer, implanterbara
Patientinformation, principer










Sök liknande artiklar

Referenser:
1. Behandlingsrekommendation. Diagnostik och behandling av kronisk hjärtsvikt. Information från Läkemedelsverket. 2006:7-87.
2. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347: 1397-1402.
3. Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A. (2009) Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. Eur Heart J 30: 671-678.
4. Cubbon RM, Gale CP, Kearney LC, Schechter CB, Brooksby WP, Nolan J, et al. Changing characteristics and mode of death associated with chronic heart failure due to left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail 2011: Epubl Mar 24.
5. The CONSENSUS Trial Study Group. (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435.
6. The SOLVD Investigators. (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302.
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821-828.
8. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al for the MERIT-HF Study Group. (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 283: 1295-1302.
9. The CIBIS-II Investigators. (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353: 9-13.
10. The MERIT-HF Investigators. (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007.
11. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334: 1349-1355.
12. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651-1658.
13. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
14. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321.
15. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11-21.
16. Cohn JN, Tognoni G. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675.
17. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 759-766.
18. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906.
19. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767-771.
20. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237.
21. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352: 1539-1549.
22. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140-2150.
23. Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. (2010) Cardiac-Resynchronization Therapy for mild-to-moderate heart failure. N Engl J Med 363: 2385-95.
24. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-847.
25. Dahlström U, Håkansson J, Swedberg K, Waldenström A. (2009) Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. Eur J Heart Fail 11: 92-8.
26. Smith JG, Koul S, Kornhall B, et al. ABC om kronisk hjärtsvikt, del 1: utredning. Läkartidningen. 2012;109:1673-7.
27. McDonagh TA, Blue L, Clark AL, Dahlström U, Ekman I, Lainscak M, et al. European society of cardiology heart failure association standards for delivering heart failure care. Eur J Heart Fail 2011; 13: 235-41.
28. Piepoli MF, Davos C, Francis DP, Coats AJ. (2004) Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 328: 189.
29. The Criteria Committee of the New York Heart Association. (1928) Diseases of the heart and blood vessels: Nomenclature and Criteria for Diagnosis. 6th edition. Boston, Mass: Little Brown.
30. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376: 875-85.
31. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376: 886-94.
32. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551.
33. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al. (2005) Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112: 2426-2435.
34. Jentzer JC, DeWald TA, Hernandez AF. (2010) Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 56: 1527-34.
35. The Digitalis Investigation Group. (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525-533.
36. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31: 2369-429.
37. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, et al. (2010) 2010 Focused Update of ESC guidelines on device therapy in heart failure: An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 31:2677-87.
38. Socialstyrelsen: Nationella riktlinjer för hjärtsjukvård - Beslutsstöd för prioriteringar. 2008.
39. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364: 1607-16.
40. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. (2011) Myocardial viability and surival in ischemic left ventricular dysfunction. N Engl J Med 364: 1617-25.
41. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G. (2007) Guidelines on the management of valvular heart disease: The task force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J 28: 230-68.
42. Harnek J, Olivecrona GK, Rück A. (2011) Kateterburen implantation av aortaklaff nytt alternativ till kirurgi. Läkartidningen 108: 1113-1116.
43. Settergren M, Nielsen NE, Jönsson A, Erlinge D, Nylander E, Harnek J. (2011) Mitralisklaffsjukdom: ”Nu kan vi både öppna och stänga”. Läkartidningen 108: 1117-1122.
44. Maron BJ, Yacoub M, Dearani JA. (2011) Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back European patients. Eur Heart J 32: 1055-8.
45. Fifer MA, Sigwart U. (2011) Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. Eur Heart J 32: 1059-64.
46. Dellgren G, Sigurdardottir V, Berg CH, Rundqvist B, Haraldsson A, Berggren H, et al. (2009) Resultaten av hjärttransplantation allt bättre. Läkartidningen 106: 3332-7.
47. Kornhall B, Nilsson J, Sigurdardottir V, Dellgren G, Hagerman I, Hübbert L. Fler hjärttransplantationer än någonsin. Läkartidningen. 2012;109:1743-4.
48. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. (2001) Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345: 1435-1443.
49. Galié N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European society of Cardiology (ESC) and the European respiratory Society (ERS). Eur Heart J 2009; 30: 2493-537.
50. Ekmehag B. Pulmonell arteriell hypertension. Nya behandlingsprinciper ger förbättrad behandling vid ett ovanligt tillstånd. Läkartidningen 2009; 106: 2057-61.
51. Khan MI. (1980) Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. Can Med Assoc J 123: 883-7.
52. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49: 675-83.
53. Hasenfuss G, Teerlink JR. (2011) Cardiac inotropes: current agents and future directions. Eur Heart J 32: 1838-45.
54. Carlsson J, Månsson A, Olsson D. (2011) Avstängning av implanterbar defibrillator - också en etisk fråga. Läkartidningen 108: 536-9.